-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Twelve drug varieties encompassing 14 dosage forms are slated for selection! Shijiazhuang Sihua Pharmaceutical has delivered an outstanding performance in the 11th round of the National Centralized Drug Procurement tender.
Category:
发布时间：2025-10-28
【概要描述】
On October 27, the highly anticipated 11th round of national centralized drug procurement was officially opened for bidding, with 14 product specifications across 12 varieties from Shijiazhuang Sihua Pharmaceutical emerging as potential winners, delivering a standout performance among the more than 400 participating companies.
On October 27, the highly anticipated 11th round of national centralized drug procurement officially commenced bidding, with 14 product specifications across 12 varieties from Shijiazhuang Sihua Pharmaceutical emerging as potential winners, demonstrating strong performance among the more than 400 participating companies.
In the 11th round of nationally organized centralized drug procurement, Shijiazhuang Sihua Pharmaceutical Co., Ltd. is slated to be selected for the following specifications and product varieties: Diprophylline Injection (2 mL: 0.3 g), Formoterol Fumarate Inhalation Solution (2 mL: 20 μg), Fluvoxamine Maleate Tablets (100 mg, 50 mg), Lornoxicam for Injection (8 mg), Epinephrine Hydrochloride Injection (1 mL: 1 mg), Bromhexine Hydrochloride Injection (2 mL: 4 mg), Compound Electrolyte Injection (500 mL), Nicorandil Tablets (5 mg), Compound Electrolyte Injection (II) (500 mL, 1,000 mL), Salbutamol Sulfate Injection (1 mL: 0.5 mg), Benidipine Hydrochloride Tablets (8 mg), and Sodium Bicarbonate Injection (50 mL: 4.2 g)—a total of 12 product varieties encompassing 14 specific specifications.
According to reports, this centralized procurement initiative covers 55 drug varieties and more than 400 pharmaceutical companies, spanning several key therapeutic areas including anti-infectives, oncology, and diabetes. Shijiazhuang Sihua Pharmaceutical has delivered particularly impressive results in this round of bidding, with a total of 14 products participating—of which 12 varieties across 14 specifications are slated for selection. Both the number of bids submitted and the number of successful selections place the company among the leaders among all participating pharmaceutical firms. Notably, Epinephrine Hydrochloride Injection (1 mL: 1 mg) and Diprophylline Injection (2 mL: 0.3 g) were both successfully awarded contracts amid fierce competition, thanks to the company’s strong market position and robust capabilities, securing top-ranking positions and fully demonstrating its brand influence and market presence.
In recent years, Shijiazhuang Sihua Pharmaceutical has regarded innovation as the key driver for enhancing drug accessibility. By pursuing integrated development of active pharmaceutical ingredients and finished dosage forms, the company has continuously refined its product portfolio and expanded both the breadth and depth of its product coverage. To date, a total of 154 drug varieties comprising 205 specifications have either passed or are deemed to have passed the consistency evaluation, laying a solid foundation for the company’s active participation in national and local centralized drug procurement initiatives.
This round of centralized procurement has undergone comprehensive rule optimization, moving away from the sole focus on awarding contracts to the lowest bidder and instead adopting a new set of principles—ensuring clinical stability, safeguarding quality, preventing bid-rigging, and countering excessive price competition. This marks the entry of national drug centralized procurement into a new phase that places greater emphasis on quality and sustainability, thereby attracting widespread attention from both society and the industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091